Logo

QIAGEN Launches Therascreen BRAF Test as CDx to a BraftovI Regimen for Metastatic Colorectal Cancer

Share this

QIAGEN Launches Therascreen BRAF Test as CDx to a BraftovI Regimen for Metastatic Colorectal Cancer

Shots:

  • QIAGEN launches its therascreen BRAF V600E RGQ PCR Kit as a CDx to Pfizer's Braftovi (encorafenib) in combination with Lilly’s Erbitux (cetuximab) for the treatment of patients with m-CRC with a BRAF V600E mutation- as detected by an FDA-approved test- after prior therapy
  • The therascreen BRAF V600E kit runs on QIAGEN’s Rotor-Gene Q MDx and detects V600E mutation which helps to identify patients eligible for treatment with the combination regimen
  • The therascreen BRAF V600E Kit will be available to accelerate the availability of innovations in precision medicine and is QIAGEN’s first CDx to obtain FDA approval for the detection of a mutation in the BRAF gene

­ Ref:  PRNewswire | Image: QIAGEN

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions